4.2 Review

The Role of the PI3K-AKT Pathway in Melanoma

期刊

CANCER JOURNAL
卷 18, 期 2, 页码 142-147

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e31824d448c

关键词

Melanoma; PI3K; AKT; PTEN; targeted therapy

类别

资金

  1. American Society of Clinical Oncology
  2. Melanoma Research Alliance
  3. GlaxoSmithKline
  4. Genentech
  5. AstraZeneca
  6. Merck
  7. Myriad

向作者/读者索取更多资源

The PI3K (phosphatidylinositol 3-kinase)-AKT pathway is one of the most important signaling networks in cancer. There is growing evidence that activation of this pathway plays a significant role in melanoma, frequently in the setting of concurrent activation of RAS-RAF-MEK-ERK signaling. This evidence includes the identification of genetic and epigenetic events that activate this pathway in melanoma cell lines and clinical specimens. In addition, functional experiments have demonstrated important roles for the PI3K-AKT pathway in both melanoma initiation and therapeutic resistance. The availability of many inhibitors against the PI3K-AKT pathway is rapidly leading to the development of trials that will ultimately determine its clinical significance in this disease. The rational development of such therapies will be facilitated by strategies that utilize the growing understanding of the complexity of the regulation and roles of this pathway.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据